title: Which Should Be the Control Arm in Trials of Antiplatelet Therapies?
authors.affiliation: Gijon, Spain.
authors.forename: Iñigo
authors.initials: I
authors.lastname: Lozano
authors.affiliation: Gijon, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Rondan
authors.affiliation: Gijon, Spain.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Vegas
authors.affiliation: Gijon, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Segovia
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives*; D026683:Advisory Committees; D003226:Congresses as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D017277:Drug Approval / Q000458:organization & administration*; D006801:Humans; D014486:United States Food and Drug Administration
chemical_list: D000249:Adenosine Monophosphate